Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 66.93 |
| Open | 67.01 |
| Bid | 66.13 x 500 |
| Ask | 66.17 x 300 |
| Day's range | 65.90 - 67.01 |
| 52-week range | 65.90 - 87.87 |
| Volume | |
| Avg. volume | 7,421,214 |
| Market cap | 82.5B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 14.70 |
| EPS (TTM) | 4.50 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 3.08 (4.66%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 79.65 |
- Reuters
US FDA mandates label updates on CAR-T cancer therapies
The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of T-cell blood cancer in patients who use these therapies. The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medication guide. In January, the FDA asked a host of drugmakers including Gilead Sciences, Johnson & Johnson and Novartis to add a boxed warning to their CAR-T cancer therapies, as it received reports of patients developing a type of T-cell blood cancer after being treated with them.
ZacksGilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.
ZacksAnalysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
